Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Abstract

We report on the outcomes of 53 patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia secondary to MDS, autografted in first complete remission. Five (9.4%) died from the procedure whereas hematological reconstitution occurred in all the remaining patients. Forty patients (75%) relapsed, with 87.5% of the relapses occurring within 2 years of the autologous transplant. With a median follow-up of 6.2 years, the median actuarial disease-free survival and overall survival were 8 and 17 months after autograft, respectively. Karyotype was the only prognostic factor for disease-free and overall survival. The eight survivors (15%), including two patients with unfavorable or intermediate karyotype, remained in first complete remission 50+ to 119+ months after transplantation and are probably cured.

• Authors: Sophie Ducastelle, Lionel Adès, Claude Gardin, Hervé Dombret, Thomas Prébet, Eric Deconinck, Bernard Rio, Xavier Thomas, Stephan Debotton, Agnès Guerci, Nicole Gratecos, Aspasia Stamatoullas, Nathalie Fegueux, François Dreyfus, Pierre Fenaux, Eric Wattel
• Journal: Haematologica (Haematologica) Vol. 91 Issue 3 Pg. 373-6 (Mar 2006) ISSN: 1592-8721 [Electronic] Italy
• PMID: 16531261 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Leukemia, Myeloid, Acute (drug therapy, mortality, surgery)
• Male
• Middle Aged
• Myelodysplastic Syndromes (drug therapy, mortality, surgery)
• Stem Cell Transplantation
• Survival Rate
• Time
• Transplantation, Autologous
• Transplantation, Homologous